Screener
Wave Life Sciences WVE HD Programs — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| INHBE program | $6,870 | $3,515 | $11,706 | $6,054 |
| AATD program | 2,989 | 1,846 | 4,739 | 3,292 |
| DMD program | 3,953 | 2,681 | 8,091 | 5,719 |
| HD program | 157 | 789 | 220 | 1,956 |
| Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM | 37,324 | 34,638 | 73,977 | 67,070 |
| Total research and development expenses | 51,293 | 43,469 | 98,733 | 84,091 |
| General and administrative expenses | 24,781 | 17,989 | 46,884 | 36,346 |
| Total operating expenses | $76,074 | $61,458 | $145,617 | $120,437 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's HD programs — research and development expense?
- Wave Life Sciences (WVE) reported HD programs — research and development expense of $157K in Q2 2026.
- How has Wave Life Sciences's HD programs — research and development expense changed year-over-year?
- Wave Life Sciences's HD programs — research and development expense decreased by 80.1% year-over-year, from $789K to $157K.
- What is the long-term trend for Wave Life Sciences's HD programs — research and development expense?
- Over 2 years (2022 to 2024), Wave Life Sciences's HD programs — research and development expense has grown at a 21.8% compound annual growth rate (CAGR), from $7.95M to $11.79M.
- What does HD programs — research and development expense mean?
- This metric represents the total operating costs directly attributable to research and development activities for the Huntington's Disease (HD) therapeutic program. It captures expenditures related to clinical trials, preclinical studies, and scientific discovery efforts specifically focused on this disease area. Monitoring this expense provides insight into the company's capital allocation strategy and the intensity of investment in its specific pipeline assets.
Ask your AI about Wave Life Sciences's hd programs — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude